A phase II study of AZD2171 (cediranib) in the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome

Patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) not fit for intensive treatment need novel therapy options. Vascular endothelial growth factor (VEGF) receptor inhibition is one potential mechanism by which AML and MDS could be treated. The receptor tyrosine kinase inhib...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Leuk Lymphoma
Autori principali: Mattison, Ryan, Jumonville, Alcee, Flynn, Patrick James, Moreno-Aspitia, Alvaro, Erlichman, Charles, Laplant, Betsy, Juckett, Mark B.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2014
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4451441/
https://ncbi.nlm.nih.gov/pubmed/25329007
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2014.977886
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi